Molecular MRI and DCE-US to evaluate anti-angiogenic therapies in kidney tumor xenografts
Ludovic de Rochefort 1 , Ingrid Leguerney 1 , Marie Poirier-Quinot 1 , Sandra Robin 1 , Xavier Violas 2 , Rose-Marie Dubuisson 1 , Stphanie Pitre-Champagnat 1 , Luc Darrasse 1 , Philippe Robert 2 , and Nathalie Lassau 1
IR4M, Univ. Paris-Sud, CNRS, UMR 8081, Orsay,
Imaging, MRI unit, Research Division, Guerbet,
A multimodal molecular MRI and DCE-US protocol was
applied in kidney tumor xenograft in mice to follow up
the response to anti-angiogenic treatments. Imaging was
performed at D0 and D3 after monoclonal anti-body,
tyrosine kinase inhibitor and m-Tor inhibitor
administration. Tumor growth, perfusion (US), diffusion,
first pass enhancement (1 min) and late enhancement (1
hour) of a targeted 3 contrast agent (MRI) were
quantified. Tumor growth was reduced with treatments.
Differences were observed in apparent diffusion
coefficient, targeted contrast agent clearance and
fixation in the different groups after treatment.
This abstract and the presentation materials are available to members only;
a login is required.